|Incidence: ||74,690 (male: 56,390; female: 18,300 Estimated new cases for 2014 in the United States) ||Stage at Presentation: |
|Stage I: ||70% |
|Stages II/III: ||25% |
|20.7 per 100,000 male and female per year (36.6 per 100,000 men, 8.9 per 100,000 women) ||Stage IV: ||5% |
|Deaths: ||Estimated 15,580 in 2014 (male: 11,170; female: 4,410) || |
|Median age: ||Seventh decade || |
|Male to female ratio: ||3:1 || |
Siegel R et al. CA Cancer J Clin 2014;64:9–29
Surveillance, Epidemiology and End Results (SEER) Program, available from http://seer.cancer.gov (accessed in 2013)
|Stage I ||H&P, cystoscopy, exam under anesthesia, transurethral resection of the bladder tumor (TURBT), and cytology. Consider CT or MRI of the abdomen and pelvis prior to TURBT if sessile or high grade. Consider upper tract imaging with either CT urogram, retrograde pyelogram, or intravenous pyelogram (IVP). Transurethral biopsy of prostate if clinically indicated |
|Stages II/III ||H&P, cystoscopy, exam under anesthesia, TURBT, and cytology. CT or MRI of the abdomen and pelvis prior to TURBT. CT of chest. Consider upper tract imaging with either CT urogram, retrograde pyelogram, or IVP. Bone scan if alkaline phosphatase is elevated or symptoms. Transurethral biopsy of prostate if clinically indicated |
|Stage IV ||H&P, cystoscopy, exam under anesthesia, TURBT, and cytology. CT or MRI of the abdomen and pelvis prior to TURBT. CT of chest. Upper tract imaging with either CT urogram, retrograde pyelogram, or IVP. Bone scan if alkaline phosphatase is elevated or symptoms |
Histopathologic evaluation should include a description of cell type(s), whether or not there are areas of differing differentiation and the extent of differentiation, whether the tumor is a micropapillary or nested variant, grade (low [G1] vs. high [G2, G3]), presence or absence of lymphatic invasion, the depth of invasion, and whether or not there is muscle in the specimen. Pathologic grade is important in the management of noninvasive tumors
McDougal WS et al. Cancer of the bladder, ureter, and renal pelvis. In: Devita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins, 2008
MVAC is the historic standard of care for systemic therapy of patients with metastatic bladder cancer based on high response rates and cure in a subset of patients. A phase III trial demonstrated that the 2-drug doublet of gemcitabine and cisplatin (GC) and MVAC are similar in response and survival but that GC has a better toxicity profile. A phase III trial compared dose dense or high dose (DD) MVAC (plus granulocyte-colony stimulating factor (G-CSF) on 2 week cycles) to standard MVAC (on a 4-week cycle) ...
Log In to View More
If your institution is currently a subscriber
of the HemOnc Collection please sign in below.
If your institution is not a subscriber
please click here
to learn more.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.